Clinical Trials Logo

Coronary Artery Bypass Graft clinical trials

View clinical trials related to Coronary Artery Bypass Graft.

Filter by:

NCT ID: NCT00863044 Completed - Clinical trials for Coronary Artery Bypass Graft

High Frequency Ventilation During Off Pump Coronary Artery Bypass Graft (CABG)

VHF
Start date: November 2009
Phase: Phase 4
Study type: Interventional

This study is to test the safety of high frequency-low volume ventilation during off pump coronary artery bypass as reflected in the near infrared spectroscopy values for cerebral oxygenation.

NCT ID: NCT00622791 Completed - Clinical trials for Coronary Artery Disease

Propofol Pharmacokinetics and Pharmacodynamics During Cardiopulmonary Bypass

Start date: n/a
Phase: N/A
Study type: Observational

Cardiopulmonary bypass (CPB) is known to alter pharmacokinetics (PK) and brain sensitivity to several drugs, including propofol. Few studies, however, have tested if propofol pharmacokinetical alterations observed after CPB could contribute to the increased hypnotic effect of propofol after CPB. This study was designed to test the hypothesis that changes in the PK of propofol contribute to an increase in its hypnotic effects after CPB as evidenced by changes in bispectral index (BIS) values. Twenty undergoing coronary artery bypass graft patients will be allocated in two groups: 1) CPB groups and 2) off-pump coronary artery bypass graft. Bispectral Index values and blood samples for plasma propofol concentration measurements will be collected along the surgery and up to 12 hours in the post-operative period. Plasma propofol concentrations, Bispectral index values and propofol PK will be compared between the groups.

NCT ID: NCT00327418 Completed - Clinical trials for Cerebrovascular Accident

CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events

CARDS
Start date: January 1997
Phase: Phase 4
Study type: Interventional

A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.

NCT ID: NCT00048308 Completed - Clinical trials for Coronary Artery Bypass Graft

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

Start date: January 2002
Phase: Phase 3
Study type: Interventional

During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.